Antisense Therapeutics Ltd. (ATHJY)

Overview

Percheron Therapeutics Limited is an Australian biopharmaceutical company focused on the research and development of novel antisense pharmaceuticals. The company, originally known as Antisense Therapeutics Limited, underwent a name change to Percheron Therapeutics Limited in December 2023. Since its incorporation in 2000, Percheron Therapeutics has dedicated itself to advancing the treatment of various diseases through its innovative antisense technology. Headquartered in Melbourne, Australia, the company continues to push the boundaries of medical research in the pursuit of new therapies for debilitating diseases.

Products and Services

• ATL1102

ATL1102 is an antisense inhibitor targeting CD49d and is currently in Phase IIa clinical trials. Its primary application is for the treatment of Duchenne Muscular Dystrophy, with potential for treating Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory conditions. By inhibiting CD49d, ATL1102 aims to reduce inflammation and improve outcomes in these diverse indications.

• Atesidorsen (ATL1103)

Atesidorsen, or ATL1103, is an oligonucleotide designed to block the expression of the growth hormone receptor, thereby reducing levels of insulin-like growth factor-I in the blood. This product has successfully completed Phase II clinical trials and is focused on treating diseases characterized by excessive growth hormone action. Its innovative approach offers hope for patients suffering from conditions associated with abnormal growth hormone levels.